Development of transplant renal artery thrombosis and signs of haemolytic-uraemic syndrome following the change from cyclosporin to tacrolimus in a renal transplant patient

Nephrology Dialysis Transplantation

Volumn 19, Issue 10, 2004, Pages 2653-2656

  Kiykim, Ahmet A ^a   Ozer, Caner ^a   Yildiz, Altan ^a   Tiftik, Naci ^a   Senli, Mehmet ^a   Kelebek, Ebru ^a   Doruk, Erdal ^a   Akbay, Erdem ^a  

^a MERSIN UNIVERSITY   (Turkey)

Author keywords

Haemolytic uraemic syndrome; Tacrolimus; Transplant renal thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; CREATININE; CYCLOSPORIN; DACLIZUMAB; DIPYRIDAMOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEBIVOLOL; PREDNISONE; SIMVASTATIN; TACROLIMUS;

ADULT; ARTICLE; CASE REPORT; DOPPLER ECHOGRAPHY; DRUG BLOOD LEVEL; FEMALE; HEMODIALYSIS; HEMOLYTIC ANEMIA; HUMAN; HYPERTENSION; KIDNEY ARTERIOGRAPHY; KIDNEY BLOOD FLOW; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; NEPHROLITHIASIS; NEPHROTOXICITY; PRIORITY JOURNAL; RENAL ARTERY THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; URINE VOLUME;

ADULT; ANGIOGRAPHY; ANGIOPLASTY, BALLOON; CYCLOSPORINE; FEMALE; FIBRINOLYTIC AGENTS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RECOMBINANT PROTEINS; RENAL ARTERY; RENAL ARTERY OBSTRUCTION; RETREATMENT; TACROLIMUS; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 5444235604     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh375     Document Type: Article

References (10)

1. Bren AF, Kandus A, Buturovic J et al. Cyclosporine-related hemolytic-uremic syndrome in kidney graft recipients: clinical and histomorphologic evaluation. Transplant Proc 1998; 30: 1201-1203
2. Reynolds JC, Agodoa LY, Yuan CM, Abbott KC. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 2003; 42: 1058-1068
3. Paul L. Overview of side effects of immunosuppressive therapy. Transplant Proc 2001; 33: 2089-2091
4. Artz MA, Boots JM, Ligtenberg G et al. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 2003; 14: 1880-1888
5. Freudenberger R, Alexis J, Gass A, Fuster V, Badimon J. Antithrombotic effect of FK506 vs cyclosporine in cardiac transplant recipients: potential implications in transplant arteriopathy. J Heart Lung Transplant 1999; 18: 1228-1231
6. Nabhan C, Kwaan HC. Current concepts in the diagnosis and management of thrombotic thrombocytopenic purpura. Hematol Oncol Clin North Am 2003; 17: 177-199
7. Lin CC, King KL, Chao YW, Yang AH, Chang CF, Yang WC. Tacrolimus-associated hemolytic uremic syndrome: a case analysis. J Nephrol 2003; 16: 580-585
8. Said T, al-Mousawi M, Samhan M, Lao M. Cyclosporin conversion to Cell-Cept in a cadaveric renal allograft recipient with hemolytic uremic syndrome. Transplant Proc 1999; 31: 3295-3297
9. Abraham KA, Little MA, Dorman AM, Walshe JJ. Hemolytic-uremic syndrome in association with both cyclosporine and tacrolimus. Transpl Int 2000; 13: 443-447
10. Furlong T, Storb T, Anasetti C et al. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Bone Marrow Transplant 2000; 26: 985-991